سعر ابيروبيسين 2مجم/مل 50 مجم فيال 50 مجم/25 مل 2026

Epirubicin hydrochloride 50 mg/25 ml (2 mg/ml) solution for intravenous infusion, 1 vial (Mylan s.a.s-france).

• Adjuvant therapy, as a component, in patients with evidence of axillary node tumour involvement following resection of primary breast cancer.Population: AdultsDailyMed (U.S. NLM)
• Directory indication: antineoplastic for treatment of cancerous tumours.

• Most common adverse reactions (>=10%): leukopenia, neutropenia, anaemia, thrombocytopenia, amenorrhoea, lethargy, nausea/vomiting, mucositis, diarrhoea, infection, conjunctivitis/keratitis, alopecia, local toxicity, rash/itch.International label, same formulation · DailyMed (U.S. NLM)

• Severe myocardial insufficiency; recent myocardial infarction; severe arrhythmias; previous treatment with anthracyclines up to the maximum cumulative dose; severe persistent drug-induced myelosuppression; severe hepatic impairment (Child-Pugh C or serum bilirubin >5 mg/dL); severe hypersensitivity to epirubicin, other anthracyclines or anthracenediones.International label, same formulation · DailyMed (U.S. NLM)

• Boxed warning - cardiac toxicity: myocardial damage including fatal congestive heart failure may occur; risk increases with cumulative dose (about 0.9% at 550 mg/m2, 1.6% at 700 mg/m2, 3.3% at 900 mg/m2); assess LVEF before, during and after therapy.International label, same formulation · DailyMed (U.S. NLM)
• Boxed warning: secondary acute myelogenous leukaemia (AML) and myelodysplastic syndrome have been reported; severe local tissue necrosis occurs with extravasation; severe myelosuppression may occur.International label, same formulation · DailyMed (U.S. NLM)

• Epirubicin can cause fetal harm when administered to a pregnant woman; advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose. Fetal/neonatal cardiotoxicity has been reported after in-utero exposure.International label, same formulation · DailyMed (U.S. NLM)
• Advise women not to breastfeed during treatment and for at least 7 days after the last dose.International label, same formulation · DailyMed (U.S. NLM)

English text not available for this section.